BREZTRI shows promise in managing COPD symptoms over 24 weeks

NCT ID NCT06422676

First seen Oct 31, 2025 · Last updated May 08, 2026 · Updated 24 times

Summary

This study followed 200 adults with moderate to severe COPD who were prescribed BREZTRI as part of their normal care. Researchers measured changes in symptoms and lung function over 24 weeks. The goal was to see how well the medication works in everyday settings.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC OBSTRUCTIVE PULMONARY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Research Site

    Blagoveshchensk, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Krasnodar, Russia

  • Research Site

    Krasnoyarsk, Russia

  • Research Site

    Moscow, Russia

  • Research Site

    Nizhny Novgorod, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Rostov-on-Don, Russia

  • Research Site

    Ryazan, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Ufa, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Yekaterinburg, Russia

Conditions

Explore the condition pages connected to this study.